CorMedix Director Janet Dillione Disposes of 10,000 Shares Amid Mixed Revenue Outlook

Janet Dillione, serving as a director of CorMedix Inc (NASDAQ: CRMD), completed a sale of 10,000 shares of the company's common stock on January 21, 2026. According to a filing with the Securities and Exchange Commission, the shares were sold at a weighted average price ranging from $6.85 to $6.90 per share, yielding a total transaction value of $68,800. Following this transaction, Dillione retains ownership of 38,473 shares in CorMedix. CorMedix has recently provided preliminary, unaudited financial results for the fourth quarter of 2025, reporting net revenues near $127 million. The full-year revenue for 2025 stood at approximately $310 million. When accounting for the Melinta acquisition on a pro forma basis, assuming the acquisition was effective from January 1, 2025, the company’s net revenue for 2025 is estimated to be around $400 million. Looking forward, CorMedix issued guidance for the 2026 fiscal year with expected revenues projected between $300 million and $320 million. This outlook would mark a decrease compared to the company’s pro forma 2025 revenue. Within this forecast, revenues from the DefenCath product are anticipated to range from $150 million to $170 million. In reaction to the revenue guidance, several market analysts have adjusted their valuations of CorMedix stock. Truist Securities lowered its price target from $20.00 to $16.00, yet retained a Buy rating, citing the 2026 revenue guidance as approximately 40% below consensus forecasts. Similarly, Leerink Partners reduced its price target from $21.00 to $15.00 while maintaining an Outperform rating, basing this on the long-term revenue prospects of the DefenCath product. Alongside financial updates, CorMedix announced recent leadership transitions. CEO Joseph Todisco has taken on the additional role as Chairman of the Board, and Mike Seckler has joined the company as Executive Vice President and Chief Commercial Officer. These changes signify a strategic realignment within the company's executive structure. This development comes during a period of scrutiny on CorMedix’s revenue trajectory and market performance. The company’s revised forecast and executive moves are elements investors and analysts will likely watch closely as they assess shareholder value and strategic execution in the coming months.